YGION Biomedical GmbH

YGION Biomedical is developing neoantigen vaccines to prevent cancer recurrence post-surgery. 

YGION has developed a proprietary neoantigen discovery platform YGNITE™ which combines next generation sequencing and in house bioinformatics to identify tumor neoantigens. Neoantigen peptides are combined with the proprietary vaccine technology CARGONAUT™ which breaks tolerance and triggers a fast and highly effective anti-tumor response.

Lead program YG-01 is a fully individualized vaccine candidate that has completed preclinical development and will enter Phase 1 clinical testing in 2026. Follow on program YG-02 targets shared neoantigens and is in discovery. 

YGION is seeking partners (collaboration, co-developing, out-licensing) for its programs and is interested in companies seeking rights in Japan, Asia or beyond

YGION Biomedicalは、術後のがん再発を予防するために、ネオアンチゲン・ペプチド・ワクチンを開発しています。 リードプログラムYG-01は、完全にカスタムメイドのワクチンで、2026年にフェーズ1の臨床試験が開始されます。